ADALTA LIMITED — Investor Relations & Filings

AdAlta Limited is a clinical-stage biotechnology company focused on the discovery and development of a new class of protein therapeutics called i-bodies. The company utilizes its proprietary i-body platform to engineer highly stable, small-format proteins that mimic the binding characteristics of shark antibodies. These i-bodies are designed to target complex disease-related proteins that are often inaccessible to traditional monoclonal antibodies. AdAlta's lead therapeutic candidate, AD-214, is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic conditions. The platform's versatility allows for the creation of diverse therapeutic leads across multiple disease areas, including inflammation and oncology, by leveraging the unique structural properties of the human protein scaffold-based i-body library.